Condition: Advanced or Recurrent Solid Tumors · FGFR Gene Alterations · Sponsor: National Cancer Center, Japan
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
This description comes directly from the study's public registry record.
Masamichi Takahashi, M.D., Ph.D. · +81-3-3542-2511 · NCCH2006_office@ml.res.ncc.go.jp
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital | Chuo-ku, Tokyo, Japan, Japan | Recruiting |
| Kanagawa Cancer Center | Yokohama, Kanagawa, Japan | Recruiting |
| Tohoku University Hospital | Aoba-ku, Sendai, Miyagi, Japan | Recruiting |
| Kyushu University Hospital | Higashi-Ku, Fukuoka, Japan | Recruiting |
| Hokkaido University Hospital | Kita-Ku, Sapporo, Hokkaido, Japan | Recruiting |
| Okayama University Hospital | Okayama, Japan | Recruiting |
| Kyoto University Hospital | Sakyo-ku, Kyoto, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04962867